amifampridine has been researched along with Anti-MuSK Myasthenia Gravis in 18 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To give an overview of the recent data on three autoimmune neuromuscular junction disorders with the recent Food Drug Administration (FDA) approval of amifampridine [3,4-Diaminopyridine (3,4-DAP) and 3,4-diaminopyridine phosphate (3,4-DAPP) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS)." | 5.12 | Neuromuscular junction disorders beyond myasthenia gravis. ( Oh, SJ, 2021) |
| " At a dosage of 18-24 mg p." | 1.27 | Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine. ( Lundh, H; Nilsson, O; Rosén, I, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, N | 1 |
| Hong, D | 1 |
| Ouyang, T | 1 |
| Meng, W | 1 |
| Huang, J | 1 |
| Li, M | 1 |
| Hong, T | 1 |
| Oh, SJ | 1 |
| Lee, MK | 1 |
| Sunwoo, IN | 1 |
| Kim, SM | 1 |
| Maselli, RA | 1 |
| Arredondo, J | 1 |
| Nguyen, J | 1 |
| Lara, M | 1 |
| Ng, F | 1 |
| Ngo, M | 1 |
| Pham, JM | 1 |
| Yi, Q | 1 |
| Stajich, JM | 1 |
| McDonald, K | 1 |
| Hauser, MA | 1 |
| Wollmann, RL | 1 |
| Evoli, A | 1 |
| Alboini, PE | 1 |
| Damato, V | 1 |
| Iorio, R | 1 |
| Argov, Z | 1 |
| Sha, SJ | 1 |
| Layzer, RB | 1 |
| Lundh, H | 3 |
| Nilsson, O | 3 |
| Rosén, I | 3 |
| Li, L | 1 |
| Zhang, YP | 2 |
| Sanders, DB | 3 |
| Howard, JF | 1 |
| Massey, JM | 2 |
| Vílchez, JJ | 1 |
| Casanova, B | 1 |
| Monte, E | 1 |
| Anlar, B | 1 |
| Varli, K | 1 |
| Ozdirim, E | 1 |
| Ertan, M | 1 |
| Sieb, JP | 1 |
| Sanders, LL | 1 |
| Edwards, LJ | 1 |
| Zheng, W | 1 |
5 reviews available for amifampridine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Topics: 4-Aminopyridine; Adult; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; | 2021 |
Neuromuscular junction disorders beyond myasthenia gravis.
Topics: Amifampridine; Antibodies; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis | 2021 |
Management of myasthenic conditions: nonimmune issues.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Humans; Myasthenia Grav | 2009 |
[Diagnosis and therapy of congenital myasthenia syndrome].
Topics: 4-Aminopyridine; Adult; Amifampridine; Central Nervous System Stimulants; Child; Cholinesterase Inhi | 1999 |
[Research progress on a new potassium channel-blocking agent--4-aminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Humans; Ion Channels; Myasthenia Gravis; Po | 1986 |
3 trials available for amifampridine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Double-Blind Method; Humans; Lambert-Eaton Myasthenic Syndrome; Myas | 1993 |
3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cross-Over Studies; Doub | 1996 |
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Action Potentials; Adult; Amifampridine; Double-Blind Method; Female; Humans; Male; | 2000 |
10 other studies available for amifampridine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cholinesterase Inhibitors; Female; Humans; Lambert-Eato | 2018 |
Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia.
Topics: 4-Aminopyridine; Aged; Amifampridine; Base Sequence; DNA Mutational Analysis; Electromyography; Exom | 2014 |
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Female; Humans; Middle Aged; Myasthenia Gravis; Rece | 2016 |
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Female; Hum | 2007 |
Novel drug of choice in Eaton-Lambert syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Female; Humans; Middle Aged; Myasthenia Gravis | 1983 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Ag | 1984 |
[Therapy of experimental autoimmune myasthenia gravis in rabbits with 4-aminopyridine and 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Action Potentials; Amifampridine; Animals; Female; Male; Myasthenia Gravis; Rabbits | 1994 |
[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
Topics: 4-Aminopyridine; Amifampridine; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potass | 1996 |
3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Topics: 4-Aminopyridine; Administration, Oral; Amifampridine; Animals; Follow-Up Studies; Humans; Lambert-Ea | 1998 |
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Dose-Response Relationship, Drug; Drug Adminis | 1985 |